Global Axillary Hyperhidrosis Drug Market

Axillary Hyperhidrosis Drug Comprehensive Study by Type (Prescription Antiperspirant, Nerve-blocking Medications, Antidepressants, Botulinum Toxin Injections, Others), Application (Clinic, Hospital, Home Care, Others), Drug Type (Botulinum ToxinA, Glycopyrrolate, Glycopyrronium Tosylate, Others), Hyperhidrosis Types (Primary Hyperhidrosis, Secondary Hyperhidrosis), Distribution Channel (Pharmaceuticals, Medical Stores, Hospitals, Others), Form (Pills, Tablets, Capsules, Liquid), Reasons (Diabetes, Menopause hot flashes, Thyroid problems, Low blood sugar, Some types of cancer, Heart attack, Nervous system disorders, Infections), Diagnosis (Blood, Urine, Other) Players and Region - Global Market Outlook to 2028

Axillary Hyperhidrosis Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Axillary Hyperhidrosis Drug Market Scope?
Hyperhidrosis is excessive sweating that goes beyond what is physiologically necessary for thermoregulation and often causes social, emotional, and work-related impairments. This condition can be primary or secondary. Primary hyperhidrosis is idiopathic, bilaterally symmetrical, excessive sweating of the armpits, palms, soles of the feet, face, and less often the scalp or groin folds. Secondary hyperhidrosis can be focal or generalized and is caused by an underlying illness or the use of medication. The doctor can prescribe an antiperspirant with aluminum chloride (Drysol, Xerac Ac). Some of the oral medications block the chemicals that allow certain nerves to communicate with each other. This can reduce sweating in some people. In addition, some of the medications for depression can also reduce sweating. Treatment by the usage of botulinum toxin (myobloc, botox, others) temporarily helps in blocking the nerves that thereby cause sweating. The effects last for six to 12 months, and then the treatment must be repeated. This treatment can be painful and some people experience temporary muscle weakness in the area being treated.

Influencing Trend:
Increasing Healthcare Spending and Demand for Drug Therapy and Growth in the Trend of Setting up Of Well-Established Health Care Facilities in Developed Regions

Market Growth Drivers:
Growing Geriatric Population in Major Economies, Increasing Awareness among People about Preventive Healthcare and The Rise in Incidence Rates of Hyperhidrosis Disorder across the Globe

Challenges:
Availability of Substitutes and Unawareness About the Disease and Treatment in the Developing Regions

Restraints:
Stringent Government Rules and Regulation and Side Effects Due to Axillary Hyperhidrosis Drug

Opportunities:
R&D and Product Innovation, The Rise in the Online Pharmacies, Potential Growth From Emerging Countries and Increasing Adoption of Western Life Style, Changing Health Care Infrastructure, And Ease in the Availability Of Therapeutic Drugs

The Axillary Hyperhidrosis Drug market study is being classified by Type (Prescription Antiperspirant, Nerve-blocking Medications, Antidepressants, Botulinum Toxin Injections and Others), by Application and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Axillary Hyperhidrosis Drug market throughout the predicted period.

Allergan Plc (Ireland), Brickell Biotech Inc. (United States), Dermira Inc. (United States), Dr. August Wolff GmbH & Co KG Arzneimittel (Germany), GlaxoSmithKline Plc (United Kingdom), TheraVida Inc. (United States), Revance Therapeutics, Inc. (United States) and Ulthera, Inc. (United States) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Axillary Hyperhidrosis Drug market by Type, Application and Region.

On the basis of geography, the market of Axillary Hyperhidrosis Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In September 2019, Brickell Biotech, Inc., a clinical-stage pharmaceutical company, merged with Vical Incorporated, following the approval of Vical's stockholders. Brickell is expected to start trading on Nasdaq Capital Market today under the ticker symbol "BBI."

First-line treatment of all primary focal hyperhidrosis, regardless of severity, is topical 20% aluminum chloride (Drysol). For craniofacial hyperhidrosis, topical 2% glycopyrrolate (compounded by a pharmacy) may be considered first-line treatment. It has shown a 96% success rate with minimal adverse effects (mild skin irritation) and can be applied once every two to three days. There are three devices registered with the U.S. Food and Drug Administration namely, RA Fischer MD-1a, RA Fischer MD-2, and Drionic. The procedure can be easily performed at home, and adverse effects (e.g., erythema, vesiculation, tingling) are typically mild and do not require cessation of the treatments. Also, there are several commercially available botulinum toxin preparations approved by the U.S. Food and Drug Administration that are available to physicians who are trained in this procedure. The most commonly used is onabotulinumtoxinA (Botox).

Key Target Audience
Manufacturers of Axillary Hyperhidrosis Drug, Suppliers and Distributors of Axillary Hyperhidrosis Drug, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others

Axillary Hyperhidrosis Drug Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Axillary Hyperhidrosis Drug Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Axillary Hyperhidrosis Drug industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Prescription Antiperspirant
  • Nerve-blocking Medications
  • Antidepressants
  • Botulinum Toxin Injections
  • Others
By Application
  • Clinic
  • Hospital
  • Home Care
  • Others
By Drug Type
  • Botulinum ToxinA
  • Glycopyrrolate
  • Glycopyrronium Tosylate
  • Others

By Hyperhidrosis Types
  • Primary Hyperhidrosis
  • Secondary Hyperhidrosis

By Distribution Channel
  • Pharmaceuticals
  • Medical Stores
  • Hospitals
  • Others

By Form
  • Pills
  • Tablets
  • Capsules
  • Liquid

By Reasons
  • Diabetes
  • Menopause hot flashes
  • Thyroid problems
  • Low blood sugar
  • Some types of cancer
  • Heart attack
  • Nervous system disorders
  • Infections

By Diagnosis
  • Blood
  • Urine
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population in Major Economies
      • 3.2.2. Increasing Awareness among People about Preventive Healthcare
      • 3.2.3. The Rise in Incidence Rates of Hyperhidrosis Disorder across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Availability of Substitutes
      • 3.3.2. Unawareness About the Disease and Treatment in the Developing Regions
    • 3.4. Market Trends
      • 3.4.1. Increasing Healthcare Spending and Demand for Drug Therapy
      • 3.4.2. Growth in the Trend of Setting up Of Well-Established Health Care Facilities in Developed Regions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Axillary Hyperhidrosis Drug, by Type, Application, Drug Type, Hyperhidrosis Types, Distribution Channel, Form, Reasons, Diagnosis and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Axillary Hyperhidrosis Drug (Value)
      • 5.2.1. Global Axillary Hyperhidrosis Drug by: Type (Value)
        • 5.2.1.1. Prescription Antiperspirant
        • 5.2.1.2. Nerve-blocking Medications
        • 5.2.1.3. Antidepressants
        • 5.2.1.4. Botulinum Toxin Injections
        • 5.2.1.5. Others
      • 5.2.2. Global Axillary Hyperhidrosis Drug by: Application (Value)
        • 5.2.2.1. Clinic
        • 5.2.2.2. Hospital
        • 5.2.2.3. Home Care
        • 5.2.2.4. Others
      • 5.2.3. Global Axillary Hyperhidrosis Drug by: Drug Type (Value)
        • 5.2.3.1. Botulinum ToxinA
        • 5.2.3.2. Glycopyrrolate
        • 5.2.3.3. Glycopyrronium Tosylate
        • 5.2.3.4. Others
      • 5.2.4. Global Axillary Hyperhidrosis Drug by: Hyperhidrosis Types (Value)
        • 5.2.4.1. Primary Hyperhidrosis
        • 5.2.4.2. Secondary Hyperhidrosis
      • 5.2.5. Global Axillary Hyperhidrosis Drug by: Distribution Channel (Value)
        • 5.2.5.1. Pharmaceuticals
        • 5.2.5.2. Medical Stores
        • 5.2.5.3. Hospitals
        • 5.2.5.4. Others
      • 5.2.6. Global Axillary Hyperhidrosis Drug by: Form (Value)
        • 5.2.6.1. Pills
        • 5.2.6.2. Tablets
        • 5.2.6.3. Capsules
        • 5.2.6.4. Liquid
      • 5.2.7. Global Axillary Hyperhidrosis Drug by: Reasons (Value)
        • 5.2.7.1. Diabetes
        • 5.2.7.2. Menopause hot flashes
        • 5.2.7.3. Thyroid problems
        • 5.2.7.4. Low blood sugar
        • 5.2.7.5. Some types of cancer
        • 5.2.7.6. Heart attack
        • 5.2.7.7. Nervous system disorders
        • 5.2.7.8. Infections
      • 5.2.8. Global Axillary Hyperhidrosis Drug by: Diagnosis (Value)
        • 5.2.8.1. Blood
        • 5.2.8.2. Urine
        • 5.2.8.3. Other
      • 5.2.9. Global Axillary Hyperhidrosis Drug Region
        • 5.2.9.1. South America
          • 5.2.9.1.1. Brazil
          • 5.2.9.1.2. Argentina
          • 5.2.9.1.3. Rest of South America
        • 5.2.9.2. Asia Pacific
          • 5.2.9.2.1. China
          • 5.2.9.2.2. Japan
          • 5.2.9.2.3. India
          • 5.2.9.2.4. South Korea
          • 5.2.9.2.5. Taiwan
          • 5.2.9.2.6. Australia
          • 5.2.9.2.7. Rest of Asia-Pacific
        • 5.2.9.3. Europe
          • 5.2.9.3.1. Germany
          • 5.2.9.3.2. France
          • 5.2.9.3.3. Italy
          • 5.2.9.3.4. United Kingdom
          • 5.2.9.3.5. Netherlands
          • 5.2.9.3.6. Rest of Europe
        • 5.2.9.4. MEA
          • 5.2.9.4.1. Middle East
          • 5.2.9.4.2. Africa
        • 5.2.9.5. North America
          • 5.2.9.5.1. United States
          • 5.2.9.5.2. Canada
          • 5.2.9.5.3. Mexico
    • 5.3. Global Axillary Hyperhidrosis Drug (Volume)
      • 5.3.1. Global Axillary Hyperhidrosis Drug by: Type (Volume)
        • 5.3.1.1. Prescription Antiperspirant
        • 5.3.1.2. Nerve-blocking Medications
        • 5.3.1.3. Antidepressants
        • 5.3.1.4. Botulinum Toxin Injections
        • 5.3.1.5. Others
      • 5.3.2. Global Axillary Hyperhidrosis Drug by: Application (Volume)
        • 5.3.2.1. Clinic
        • 5.3.2.2. Hospital
        • 5.3.2.3. Home Care
        • 5.3.2.4. Others
      • 5.3.3. Global Axillary Hyperhidrosis Drug by: Drug Type (Volume)
        • 5.3.3.1. Botulinum ToxinA
        • 5.3.3.2. Glycopyrrolate
        • 5.3.3.3. Glycopyrronium Tosylate
        • 5.3.3.4. Others
      • 5.3.4. Global Axillary Hyperhidrosis Drug by: Hyperhidrosis Types (Volume)
        • 5.3.4.1. Primary Hyperhidrosis
        • 5.3.4.2. Secondary Hyperhidrosis
      • 5.3.5. Global Axillary Hyperhidrosis Drug by: Distribution Channel (Volume)
        • 5.3.5.1. Pharmaceuticals
        • 5.3.5.2. Medical Stores
        • 5.3.5.3. Hospitals
        • 5.3.5.4. Others
      • 5.3.6. Global Axillary Hyperhidrosis Drug by: Form (Volume)
        • 5.3.6.1. Pills
        • 5.3.6.2. Tablets
        • 5.3.6.3. Capsules
        • 5.3.6.4. Liquid
      • 5.3.7. Global Axillary Hyperhidrosis Drug by: Reasons (Volume)
        • 5.3.7.1. Diabetes
        • 5.3.7.2. Menopause hot flashes
        • 5.3.7.3. Thyroid problems
        • 5.3.7.4. Low blood sugar
        • 5.3.7.5. Some types of cancer
        • 5.3.7.6. Heart attack
        • 5.3.7.7. Nervous system disorders
        • 5.3.7.8. Infections
      • 5.3.8. Global Axillary Hyperhidrosis Drug by: Diagnosis (Volume)
        • 5.3.8.1. Blood
        • 5.3.8.2. Urine
        • 5.3.8.3. Other
      • 5.3.9. Global Axillary Hyperhidrosis Drug Region
        • 5.3.9.1. South America
          • 5.3.9.1.1. Brazil
          • 5.3.9.1.2. Argentina
          • 5.3.9.1.3. Rest of South America
        • 5.3.9.2. Asia Pacific
          • 5.3.9.2.1. China
          • 5.3.9.2.2. Japan
          • 5.3.9.2.3. India
          • 5.3.9.2.4. South Korea
          • 5.3.9.2.5. Taiwan
          • 5.3.9.2.6. Australia
          • 5.3.9.2.7. Rest of Asia-Pacific
        • 5.3.9.3. Europe
          • 5.3.9.3.1. Germany
          • 5.3.9.3.2. France
          • 5.3.9.3.3. Italy
          • 5.3.9.3.4. United Kingdom
          • 5.3.9.3.5. Netherlands
          • 5.3.9.3.6. Rest of Europe
        • 5.3.9.4. MEA
          • 5.3.9.4.1. Middle East
          • 5.3.9.4.2. Africa
        • 5.3.9.5. North America
          • 5.3.9.5.1. United States
          • 5.3.9.5.2. Canada
          • 5.3.9.5.3. Mexico
    • 5.4. Global Axillary Hyperhidrosis Drug (Price)
      • 5.4.1. Global Axillary Hyperhidrosis Drug by: Type (Price)
  • 6. Axillary Hyperhidrosis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Brickell Biotech Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dermira Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Dr. August Wolff GmbH & Co KG Arzneimittel (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. TheraVida Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Revance Therapeutics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Ulthera, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Axillary Hyperhidrosis Drug Sale, by Type, Application, Drug Type, Hyperhidrosis Types, Distribution Channel, Form, Reasons, Diagnosis and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Axillary Hyperhidrosis Drug (Value)
      • 7.2.1. Global Axillary Hyperhidrosis Drug by: Type (Value)
        • 7.2.1.1. Prescription Antiperspirant
        • 7.2.1.2. Nerve-blocking Medications
        • 7.2.1.3. Antidepressants
        • 7.2.1.4. Botulinum Toxin Injections
        • 7.2.1.5. Others
      • 7.2.2. Global Axillary Hyperhidrosis Drug by: Application (Value)
        • 7.2.2.1. Clinic
        • 7.2.2.2. Hospital
        • 7.2.2.3. Home Care
        • 7.2.2.4. Others
      • 7.2.3. Global Axillary Hyperhidrosis Drug by: Drug Type (Value)
        • 7.2.3.1. Botulinum ToxinA
        • 7.2.3.2. Glycopyrrolate
        • 7.2.3.3. Glycopyrronium Tosylate
        • 7.2.3.4. Others
      • 7.2.4. Global Axillary Hyperhidrosis Drug by: Hyperhidrosis Types (Value)
        • 7.2.4.1. Primary Hyperhidrosis
        • 7.2.4.2. Secondary Hyperhidrosis
      • 7.2.5. Global Axillary Hyperhidrosis Drug by: Distribution Channel (Value)
        • 7.2.5.1. Pharmaceuticals
        • 7.2.5.2. Medical Stores
        • 7.2.5.3. Hospitals
        • 7.2.5.4. Others
      • 7.2.6. Global Axillary Hyperhidrosis Drug by: Form (Value)
        • 7.2.6.1. Pills
        • 7.2.6.2. Tablets
        • 7.2.6.3. Capsules
        • 7.2.6.4. Liquid
      • 7.2.7. Global Axillary Hyperhidrosis Drug by: Reasons (Value)
        • 7.2.7.1. Diabetes
        • 7.2.7.2. Menopause hot flashes
        • 7.2.7.3. Thyroid problems
        • 7.2.7.4. Low blood sugar
        • 7.2.7.5. Some types of cancer
        • 7.2.7.6. Heart attack
        • 7.2.7.7. Nervous system disorders
        • 7.2.7.8. Infections
      • 7.2.8. Global Axillary Hyperhidrosis Drug by: Diagnosis (Value)
        • 7.2.8.1. Blood
        • 7.2.8.2. Urine
        • 7.2.8.3. Other
      • 7.2.9. Global Axillary Hyperhidrosis Drug Region
        • 7.2.9.1. South America
          • 7.2.9.1.1. Brazil
          • 7.2.9.1.2. Argentina
          • 7.2.9.1.3. Rest of South America
        • 7.2.9.2. Asia Pacific
          • 7.2.9.2.1. China
          • 7.2.9.2.2. Japan
          • 7.2.9.2.3. India
          • 7.2.9.2.4. South Korea
          • 7.2.9.2.5. Taiwan
          • 7.2.9.2.6. Australia
          • 7.2.9.2.7. Rest of Asia-Pacific
        • 7.2.9.3. Europe
          • 7.2.9.3.1. Germany
          • 7.2.9.3.2. France
          • 7.2.9.3.3. Italy
          • 7.2.9.3.4. United Kingdom
          • 7.2.9.3.5. Netherlands
          • 7.2.9.3.6. Rest of Europe
        • 7.2.9.4. MEA
          • 7.2.9.4.1. Middle East
          • 7.2.9.4.2. Africa
        • 7.2.9.5. North America
          • 7.2.9.5.1. United States
          • 7.2.9.5.2. Canada
          • 7.2.9.5.3. Mexico
    • 7.3. Global Axillary Hyperhidrosis Drug (Volume)
      • 7.3.1. Global Axillary Hyperhidrosis Drug by: Type (Volume)
        • 7.3.1.1. Prescription Antiperspirant
        • 7.3.1.2. Nerve-blocking Medications
        • 7.3.1.3. Antidepressants
        • 7.3.1.4. Botulinum Toxin Injections
        • 7.3.1.5. Others
      • 7.3.2. Global Axillary Hyperhidrosis Drug by: Application (Volume)
        • 7.3.2.1. Clinic
        • 7.3.2.2. Hospital
        • 7.3.2.3. Home Care
        • 7.3.2.4. Others
      • 7.3.3. Global Axillary Hyperhidrosis Drug by: Drug Type (Volume)
        • 7.3.3.1. Botulinum ToxinA
        • 7.3.3.2. Glycopyrrolate
        • 7.3.3.3. Glycopyrronium Tosylate
        • 7.3.3.4. Others
      • 7.3.4. Global Axillary Hyperhidrosis Drug by: Hyperhidrosis Types (Volume)
        • 7.3.4.1. Primary Hyperhidrosis
        • 7.3.4.2. Secondary Hyperhidrosis
      • 7.3.5. Global Axillary Hyperhidrosis Drug by: Distribution Channel (Volume)
        • 7.3.5.1. Pharmaceuticals
        • 7.3.5.2. Medical Stores
        • 7.3.5.3. Hospitals
        • 7.3.5.4. Others
      • 7.3.6. Global Axillary Hyperhidrosis Drug by: Form (Volume)
        • 7.3.6.1. Pills
        • 7.3.6.2. Tablets
        • 7.3.6.3. Capsules
        • 7.3.6.4. Liquid
      • 7.3.7. Global Axillary Hyperhidrosis Drug by: Reasons (Volume)
        • 7.3.7.1. Diabetes
        • 7.3.7.2. Menopause hot flashes
        • 7.3.7.3. Thyroid problems
        • 7.3.7.4. Low blood sugar
        • 7.3.7.5. Some types of cancer
        • 7.3.7.6. Heart attack
        • 7.3.7.7. Nervous system disorders
        • 7.3.7.8. Infections
      • 7.3.8. Global Axillary Hyperhidrosis Drug by: Diagnosis (Volume)
        • 7.3.8.1. Blood
        • 7.3.8.2. Urine
        • 7.3.8.3. Other
      • 7.3.9. Global Axillary Hyperhidrosis Drug Region
        • 7.3.9.1. South America
          • 7.3.9.1.1. Brazil
          • 7.3.9.1.2. Argentina
          • 7.3.9.1.3. Rest of South America
        • 7.3.9.2. Asia Pacific
          • 7.3.9.2.1. China
          • 7.3.9.2.2. Japan
          • 7.3.9.2.3. India
          • 7.3.9.2.4. South Korea
          • 7.3.9.2.5. Taiwan
          • 7.3.9.2.6. Australia
          • 7.3.9.2.7. Rest of Asia-Pacific
        • 7.3.9.3. Europe
          • 7.3.9.3.1. Germany
          • 7.3.9.3.2. France
          • 7.3.9.3.3. Italy
          • 7.3.9.3.4. United Kingdom
          • 7.3.9.3.5. Netherlands
          • 7.3.9.3.6. Rest of Europe
        • 7.3.9.4. MEA
          • 7.3.9.4.1. Middle East
          • 7.3.9.4.2. Africa
        • 7.3.9.5. North America
          • 7.3.9.5.1. United States
          • 7.3.9.5.2. Canada
          • 7.3.9.5.3. Mexico
    • 7.4. Global Axillary Hyperhidrosis Drug (Price)
      • 7.4.1. Global Axillary Hyperhidrosis Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Axillary Hyperhidrosis Drug: by Type(USD Million)
  • Table 2. Axillary Hyperhidrosis Drug Prescription Antiperspirant , by Region USD Million (2017-2022)
  • Table 3. Axillary Hyperhidrosis Drug Nerve-blocking Medications , by Region USD Million (2017-2022)
  • Table 4. Axillary Hyperhidrosis Drug Antidepressants , by Region USD Million (2017-2022)
  • Table 5. Axillary Hyperhidrosis Drug Botulinum Toxin Injections , by Region USD Million (2017-2022)
  • Table 6. Axillary Hyperhidrosis Drug Others , by Region USD Million (2017-2022)
  • Table 7. Axillary Hyperhidrosis Drug: by Application(USD Million)
  • Table 8. Axillary Hyperhidrosis Drug Clinic , by Region USD Million (2017-2022)
  • Table 9. Axillary Hyperhidrosis Drug Hospital , by Region USD Million (2017-2022)
  • Table 10. Axillary Hyperhidrosis Drug Home Care , by Region USD Million (2017-2022)
  • Table 11. Axillary Hyperhidrosis Drug Others , by Region USD Million (2017-2022)
  • Table 12. Axillary Hyperhidrosis Drug: by Drug Type(USD Million)
  • Table 13. Axillary Hyperhidrosis Drug Botulinum ToxinA , by Region USD Million (2017-2022)
  • Table 14. Axillary Hyperhidrosis Drug Glycopyrrolate , by Region USD Million (2017-2022)
  • Table 15. Axillary Hyperhidrosis Drug Glycopyrronium Tosylate , by Region USD Million (2017-2022)
  • Table 16. Axillary Hyperhidrosis Drug Others , by Region USD Million (2017-2022)
  • Table 17. Axillary Hyperhidrosis Drug: by Hyperhidrosis Types(USD Million)
  • Table 18. Axillary Hyperhidrosis Drug Primary Hyperhidrosis , by Region USD Million (2017-2022)
  • Table 19. Axillary Hyperhidrosis Drug Secondary Hyperhidrosis , by Region USD Million (2017-2022)
  • Table 20. Axillary Hyperhidrosis Drug: by Distribution Channel(USD Million)
  • Table 21. Axillary Hyperhidrosis Drug Pharmaceuticals , by Region USD Million (2017-2022)
  • Table 22. Axillary Hyperhidrosis Drug Medical Stores , by Region USD Million (2017-2022)
  • Table 23. Axillary Hyperhidrosis Drug Hospitals , by Region USD Million (2017-2022)
  • Table 24. Axillary Hyperhidrosis Drug Others , by Region USD Million (2017-2022)
  • Table 25. Axillary Hyperhidrosis Drug: by Form(USD Million)
  • Table 26. Axillary Hyperhidrosis Drug Pills , by Region USD Million (2017-2022)
  • Table 27. Axillary Hyperhidrosis Drug Tablets , by Region USD Million (2017-2022)
  • Table 28. Axillary Hyperhidrosis Drug Capsules , by Region USD Million (2017-2022)
  • Table 29. Axillary Hyperhidrosis Drug Liquid , by Region USD Million (2017-2022)
  • Table 30. Axillary Hyperhidrosis Drug: by Reasons(USD Million)
  • Table 31. Axillary Hyperhidrosis Drug Diabetes , by Region USD Million (2017-2022)
  • Table 32. Axillary Hyperhidrosis Drug Menopause hot flashes , by Region USD Million (2017-2022)
  • Table 33. Axillary Hyperhidrosis Drug Thyroid problems , by Region USD Million (2017-2022)
  • Table 34. Axillary Hyperhidrosis Drug Low blood sugar , by Region USD Million (2017-2022)
  • Table 35. Axillary Hyperhidrosis Drug Some types of cancer , by Region USD Million (2017-2022)
  • Table 36. Axillary Hyperhidrosis Drug Heart attack , by Region USD Million (2017-2022)
  • Table 37. Axillary Hyperhidrosis Drug Nervous system disorders , by Region USD Million (2017-2022)
  • Table 38. Axillary Hyperhidrosis Drug Infections , by Region USD Million (2017-2022)
  • Table 39. Axillary Hyperhidrosis Drug: by Diagnosis(USD Million)
  • Table 40. Axillary Hyperhidrosis Drug Blood , by Region USD Million (2017-2022)
  • Table 41. Axillary Hyperhidrosis Drug Urine , by Region USD Million (2017-2022)
  • Table 42. Axillary Hyperhidrosis Drug Other , by Region USD Million (2017-2022)
  • Table 43. South America Axillary Hyperhidrosis Drug, by Country USD Million (2017-2022)
  • Table 44. South America Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 45. South America Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 46. South America Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 47. South America Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 48. South America Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 49. South America Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 50. South America Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 51. South America Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 52. Brazil Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 53. Brazil Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 54. Brazil Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 55. Brazil Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 56. Brazil Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 57. Brazil Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 58. Brazil Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 59. Brazil Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 60. Argentina Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 61. Argentina Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 62. Argentina Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 63. Argentina Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 64. Argentina Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 65. Argentina Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 66. Argentina Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 67. Argentina Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 68. Rest of South America Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 69. Rest of South America Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 70. Rest of South America Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 71. Rest of South America Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 72. Rest of South America Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 73. Rest of South America Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 74. Rest of South America Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 75. Rest of South America Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 76. Asia Pacific Axillary Hyperhidrosis Drug, by Country USD Million (2017-2022)
  • Table 77. Asia Pacific Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 78. Asia Pacific Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 79. Asia Pacific Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 80. Asia Pacific Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 81. Asia Pacific Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 82. Asia Pacific Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 83. Asia Pacific Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 84. Asia Pacific Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 85. China Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 86. China Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 87. China Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 88. China Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 89. China Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 90. China Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 91. China Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 92. China Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 93. Japan Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 94. Japan Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 95. Japan Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 96. Japan Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 97. Japan Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 98. Japan Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 99. Japan Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 100. Japan Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 101. India Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 102. India Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 103. India Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 104. India Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 105. India Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 106. India Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 107. India Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 108. India Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 109. South Korea Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 110. South Korea Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 111. South Korea Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 112. South Korea Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 113. South Korea Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 114. South Korea Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 115. South Korea Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 116. South Korea Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 117. Taiwan Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 118. Taiwan Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 119. Taiwan Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 120. Taiwan Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 121. Taiwan Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 122. Taiwan Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 123. Taiwan Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 124. Taiwan Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 125. Australia Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 126. Australia Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 127. Australia Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 128. Australia Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 129. Australia Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 130. Australia Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 131. Australia Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 132. Australia Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 133. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 134. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 135. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 136. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 137. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 138. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 139. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 140. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 141. Europe Axillary Hyperhidrosis Drug, by Country USD Million (2017-2022)
  • Table 142. Europe Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 143. Europe Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 144. Europe Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 145. Europe Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 146. Europe Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 147. Europe Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 148. Europe Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 149. Europe Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 150. Germany Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 151. Germany Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 152. Germany Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 153. Germany Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 154. Germany Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 155. Germany Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 156. Germany Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 157. Germany Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 158. France Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 159. France Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 160. France Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 161. France Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 162. France Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 163. France Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 164. France Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 165. France Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 166. Italy Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 167. Italy Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 168. Italy Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 169. Italy Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 170. Italy Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 171. Italy Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 172. Italy Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 173. Italy Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 174. United Kingdom Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 175. United Kingdom Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 176. United Kingdom Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 177. United Kingdom Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 178. United Kingdom Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 179. United Kingdom Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 180. United Kingdom Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 181. United Kingdom Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 182. Netherlands Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 183. Netherlands Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 184. Netherlands Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 185. Netherlands Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 186. Netherlands Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 187. Netherlands Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 188. Netherlands Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 189. Netherlands Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 190. Rest of Europe Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 191. Rest of Europe Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 192. Rest of Europe Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 193. Rest of Europe Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 194. Rest of Europe Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 195. Rest of Europe Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 196. Rest of Europe Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 197. Rest of Europe Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 198. MEA Axillary Hyperhidrosis Drug, by Country USD Million (2017-2022)
  • Table 199. MEA Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 200. MEA Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 201. MEA Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 202. MEA Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 203. MEA Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 204. MEA Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 205. MEA Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 206. MEA Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 207. Middle East Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 208. Middle East Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 209. Middle East Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 210. Middle East Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 211. Middle East Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 212. Middle East Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 213. Middle East Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 214. Middle East Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 215. Africa Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 216. Africa Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 217. Africa Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 218. Africa Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 219. Africa Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 220. Africa Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 221. Africa Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 222. Africa Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 223. North America Axillary Hyperhidrosis Drug, by Country USD Million (2017-2022)
  • Table 224. North America Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 225. North America Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 226. North America Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 227. North America Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 228. North America Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 229. North America Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 230. North America Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 231. North America Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 232. United States Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 233. United States Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 234. United States Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 235. United States Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 236. United States Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 237. United States Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 238. United States Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 239. United States Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 240. Canada Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 241. Canada Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 242. Canada Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 243. Canada Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 244. Canada Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 245. Canada Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 246. Canada Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 247. Canada Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 248. Mexico Axillary Hyperhidrosis Drug, by Type USD Million (2017-2022)
  • Table 249. Mexico Axillary Hyperhidrosis Drug, by Application USD Million (2017-2022)
  • Table 250. Mexico Axillary Hyperhidrosis Drug, by Drug Type USD Million (2017-2022)
  • Table 251. Mexico Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2017-2022)
  • Table 252. Mexico Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2017-2022)
  • Table 253. Mexico Axillary Hyperhidrosis Drug, by Form USD Million (2017-2022)
  • Table 254. Mexico Axillary Hyperhidrosis Drug, by Reasons USD Million (2017-2022)
  • Table 255. Mexico Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2017-2022)
  • Table 256. Axillary Hyperhidrosis Drug Sales: by Type(K Tons)
  • Table 257. Axillary Hyperhidrosis Drug Sales Prescription Antiperspirant , by Region K Tons (2017-2022)
  • Table 258. Axillary Hyperhidrosis Drug Sales Nerve-blocking Medications , by Region K Tons (2017-2022)
  • Table 259. Axillary Hyperhidrosis Drug Sales Antidepressants , by Region K Tons (2017-2022)
  • Table 260. Axillary Hyperhidrosis Drug Sales Botulinum Toxin Injections , by Region K Tons (2017-2022)
  • Table 261. Axillary Hyperhidrosis Drug Sales Others , by Region K Tons (2017-2022)
  • Table 262. Axillary Hyperhidrosis Drug Sales: by Application(K Tons)
  • Table 263. Axillary Hyperhidrosis Drug Sales Clinic , by Region K Tons (2017-2022)
  • Table 264. Axillary Hyperhidrosis Drug Sales Hospital , by Region K Tons (2017-2022)
  • Table 265. Axillary Hyperhidrosis Drug Sales Home Care , by Region K Tons (2017-2022)
  • Table 266. Axillary Hyperhidrosis Drug Sales Others , by Region K Tons (2017-2022)
  • Table 267. Axillary Hyperhidrosis Drug Sales: by Drug Type(K Tons)
  • Table 268. Axillary Hyperhidrosis Drug Sales Botulinum ToxinA , by Region K Tons (2017-2022)
  • Table 269. Axillary Hyperhidrosis Drug Sales Glycopyrrolate , by Region K Tons (2017-2022)
  • Table 270. Axillary Hyperhidrosis Drug Sales Glycopyrronium Tosylate , by Region K Tons (2017-2022)
  • Table 271. Axillary Hyperhidrosis Drug Sales Others , by Region K Tons (2017-2022)
  • Table 272. Axillary Hyperhidrosis Drug Sales: by Hyperhidrosis Types(K Tons)
  • Table 273. Axillary Hyperhidrosis Drug Sales Primary Hyperhidrosis , by Region K Tons (2017-2022)
  • Table 274. Axillary Hyperhidrosis Drug Sales Secondary Hyperhidrosis , by Region K Tons (2017-2022)
  • Table 275. Axillary Hyperhidrosis Drug Sales: by Distribution Channel(K Tons)
  • Table 276. Axillary Hyperhidrosis Drug Sales Pharmaceuticals , by Region K Tons (2017-2022)
  • Table 277. Axillary Hyperhidrosis Drug Sales Medical Stores , by Region K Tons (2017-2022)
  • Table 278. Axillary Hyperhidrosis Drug Sales Hospitals , by Region K Tons (2017-2022)
  • Table 279. Axillary Hyperhidrosis Drug Sales Others , by Region K Tons (2017-2022)
  • Table 280. Axillary Hyperhidrosis Drug Sales: by Form(K Tons)
  • Table 281. Axillary Hyperhidrosis Drug Sales Pills , by Region K Tons (2017-2022)
  • Table 282. Axillary Hyperhidrosis Drug Sales Tablets , by Region K Tons (2017-2022)
  • Table 283. Axillary Hyperhidrosis Drug Sales Capsules , by Region K Tons (2017-2022)
  • Table 284. Axillary Hyperhidrosis Drug Sales Liquid , by Region K Tons (2017-2022)
  • Table 285. Axillary Hyperhidrosis Drug Sales: by Reasons(K Tons)
  • Table 286. Axillary Hyperhidrosis Drug Sales Diabetes , by Region K Tons (2017-2022)
  • Table 287. Axillary Hyperhidrosis Drug Sales Menopause hot flashes , by Region K Tons (2017-2022)
  • Table 288. Axillary Hyperhidrosis Drug Sales Thyroid problems , by Region K Tons (2017-2022)
  • Table 289. Axillary Hyperhidrosis Drug Sales Low blood sugar , by Region K Tons (2017-2022)
  • Table 290. Axillary Hyperhidrosis Drug Sales Some types of cancer , by Region K Tons (2017-2022)
  • Table 291. Axillary Hyperhidrosis Drug Sales Heart attack , by Region K Tons (2017-2022)
  • Table 292. Axillary Hyperhidrosis Drug Sales Nervous system disorders , by Region K Tons (2017-2022)
  • Table 293. Axillary Hyperhidrosis Drug Sales Infections , by Region K Tons (2017-2022)
  • Table 294. Axillary Hyperhidrosis Drug Sales: by Diagnosis(K Tons)
  • Table 295. Axillary Hyperhidrosis Drug Sales Blood , by Region K Tons (2017-2022)
  • Table 296. Axillary Hyperhidrosis Drug Sales Urine , by Region K Tons (2017-2022)
  • Table 297. Axillary Hyperhidrosis Drug Sales Other , by Region K Tons (2017-2022)
  • Table 298. South America Axillary Hyperhidrosis Drug Sales, by Country K Tons (2017-2022)
  • Table 299. South America Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 300. South America Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 301. South America Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 302. South America Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 303. South America Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 304. South America Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 305. South America Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 306. South America Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 307. Brazil Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 308. Brazil Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 309. Brazil Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 310. Brazil Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 311. Brazil Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 312. Brazil Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 313. Brazil Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 314. Brazil Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 315. Argentina Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 316. Argentina Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 317. Argentina Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 318. Argentina Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 319. Argentina Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 320. Argentina Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 321. Argentina Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 322. Argentina Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 323. Rest of South America Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 324. Rest of South America Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 325. Rest of South America Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 326. Rest of South America Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 327. Rest of South America Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 328. Rest of South America Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 329. Rest of South America Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 330. Rest of South America Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 331. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Country K Tons (2017-2022)
  • Table 332. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 333. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 334. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 335. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 336. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 337. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 338. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 339. Asia Pacific Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 340. China Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 341. China Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 342. China Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 343. China Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 344. China Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 345. China Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 346. China Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 347. China Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 348. Japan Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 349. Japan Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 350. Japan Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 351. Japan Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 352. Japan Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 353. Japan Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 354. Japan Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 355. Japan Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 356. India Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 357. India Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 358. India Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 359. India Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 360. India Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 361. India Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 362. India Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 363. India Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 364. South Korea Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 365. South Korea Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 366. South Korea Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 367. South Korea Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 368. South Korea Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 369. South Korea Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 370. South Korea Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 371. South Korea Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 372. Taiwan Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 373. Taiwan Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 374. Taiwan Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 375. Taiwan Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 376. Taiwan Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 377. Taiwan Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 378. Taiwan Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 379. Taiwan Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 380. Australia Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 381. Australia Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 382. Australia Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 383. Australia Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 384. Australia Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 385. Australia Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 386. Australia Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 387. Australia Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 388. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 389. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 390. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 391. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 392. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 393. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 394. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 395. Rest of Asia-Pacific Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 396. Europe Axillary Hyperhidrosis Drug Sales, by Country K Tons (2017-2022)
  • Table 397. Europe Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 398. Europe Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 399. Europe Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 400. Europe Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 401. Europe Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 402. Europe Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 403. Europe Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 404. Europe Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 405. Germany Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 406. Germany Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 407. Germany Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 408. Germany Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 409. Germany Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 410. Germany Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 411. Germany Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 412. Germany Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 413. France Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 414. France Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 415. France Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 416. France Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 417. France Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 418. France Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 419. France Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 420. France Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 421. Italy Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 422. Italy Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 423. Italy Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 424. Italy Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 425. Italy Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 426. Italy Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 427. Italy Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 428. Italy Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 429. United Kingdom Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 430. United Kingdom Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 431. United Kingdom Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 432. United Kingdom Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 433. United Kingdom Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 434. United Kingdom Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 435. United Kingdom Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 436. United Kingdom Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 437. Netherlands Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 438. Netherlands Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 439. Netherlands Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 440. Netherlands Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 441. Netherlands Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 442. Netherlands Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 443. Netherlands Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 444. Netherlands Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 445. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 446. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 447. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 448. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 449. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 450. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 451. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 452. Rest of Europe Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 453. MEA Axillary Hyperhidrosis Drug Sales, by Country K Tons (2017-2022)
  • Table 454. MEA Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 455. MEA Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 456. MEA Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 457. MEA Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 458. MEA Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 459. MEA Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 460. MEA Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 461. MEA Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 462. Middle East Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 463. Middle East Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 464. Middle East Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 465. Middle East Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 466. Middle East Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 467. Middle East Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 468. Middle East Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 469. Middle East Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 470. Africa Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 471. Africa Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 472. Africa Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 473. Africa Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 474. Africa Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 475. Africa Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 476. Africa Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 477. Africa Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 478. North America Axillary Hyperhidrosis Drug Sales, by Country K Tons (2017-2022)
  • Table 479. North America Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 480. North America Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 481. North America Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 482. North America Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 483. North America Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 484. North America Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 485. North America Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 486. North America Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 487. United States Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 488. United States Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 489. United States Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 490. United States Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 491. United States Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 492. United States Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 493. United States Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 494. United States Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 495. Canada Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 496. Canada Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 497. Canada Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 498. Canada Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 499. Canada Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 500. Canada Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 501. Canada Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 502. Canada Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 503. Mexico Axillary Hyperhidrosis Drug Sales, by Type K Tons (2017-2022)
  • Table 504. Mexico Axillary Hyperhidrosis Drug Sales, by Application K Tons (2017-2022)
  • Table 505. Mexico Axillary Hyperhidrosis Drug Sales, by Drug Type K Tons (2017-2022)
  • Table 506. Mexico Axillary Hyperhidrosis Drug Sales, by Hyperhidrosis Types K Tons (2017-2022)
  • Table 507. Mexico Axillary Hyperhidrosis Drug Sales, by Distribution Channel K Tons (2017-2022)
  • Table 508. Mexico Axillary Hyperhidrosis Drug Sales, by Form K Tons (2017-2022)
  • Table 509. Mexico Axillary Hyperhidrosis Drug Sales, by Reasons K Tons (2017-2022)
  • Table 510. Mexico Axillary Hyperhidrosis Drug Sales, by Diagnosis K Tons (2017-2022)
  • Table 511. Axillary Hyperhidrosis Drug: by Type(USD/Units)
  • Table 512. Company Basic Information, Sales Area and Its Competitors
  • Table 513. Company Basic Information, Sales Area and Its Competitors
  • Table 514. Company Basic Information, Sales Area and Its Competitors
  • Table 515. Company Basic Information, Sales Area and Its Competitors
  • Table 516. Company Basic Information, Sales Area and Its Competitors
  • Table 517. Company Basic Information, Sales Area and Its Competitors
  • Table 518. Company Basic Information, Sales Area and Its Competitors
  • Table 519. Company Basic Information, Sales Area and Its Competitors
  • Table 520. Axillary Hyperhidrosis Drug: by Type(USD Million)
  • Table 521. Axillary Hyperhidrosis Drug Prescription Antiperspirant , by Region USD Million (2023-2028)
  • Table 522. Axillary Hyperhidrosis Drug Nerve-blocking Medications , by Region USD Million (2023-2028)
  • Table 523. Axillary Hyperhidrosis Drug Antidepressants , by Region USD Million (2023-2028)
  • Table 524. Axillary Hyperhidrosis Drug Botulinum Toxin Injections , by Region USD Million (2023-2028)
  • Table 525. Axillary Hyperhidrosis Drug Others , by Region USD Million (2023-2028)
  • Table 526. Axillary Hyperhidrosis Drug: by Application(USD Million)
  • Table 527. Axillary Hyperhidrosis Drug Clinic , by Region USD Million (2023-2028)
  • Table 528. Axillary Hyperhidrosis Drug Hospital , by Region USD Million (2023-2028)
  • Table 529. Axillary Hyperhidrosis Drug Home Care , by Region USD Million (2023-2028)
  • Table 530. Axillary Hyperhidrosis Drug Others , by Region USD Million (2023-2028)
  • Table 531. Axillary Hyperhidrosis Drug: by Drug Type(USD Million)
  • Table 532. Axillary Hyperhidrosis Drug Botulinum ToxinA , by Region USD Million (2023-2028)
  • Table 533. Axillary Hyperhidrosis Drug Glycopyrrolate , by Region USD Million (2023-2028)
  • Table 534. Axillary Hyperhidrosis Drug Glycopyrronium Tosylate , by Region USD Million (2023-2028)
  • Table 535. Axillary Hyperhidrosis Drug Others , by Region USD Million (2023-2028)
  • Table 536. Axillary Hyperhidrosis Drug: by Hyperhidrosis Types(USD Million)
  • Table 537. Axillary Hyperhidrosis Drug Primary Hyperhidrosis , by Region USD Million (2023-2028)
  • Table 538. Axillary Hyperhidrosis Drug Secondary Hyperhidrosis , by Region USD Million (2023-2028)
  • Table 539. Axillary Hyperhidrosis Drug: by Distribution Channel(USD Million)
  • Table 540. Axillary Hyperhidrosis Drug Pharmaceuticals , by Region USD Million (2023-2028)
  • Table 541. Axillary Hyperhidrosis Drug Medical Stores , by Region USD Million (2023-2028)
  • Table 542. Axillary Hyperhidrosis Drug Hospitals , by Region USD Million (2023-2028)
  • Table 543. Axillary Hyperhidrosis Drug Others , by Region USD Million (2023-2028)
  • Table 544. Axillary Hyperhidrosis Drug: by Form(USD Million)
  • Table 545. Axillary Hyperhidrosis Drug Pills , by Region USD Million (2023-2028)
  • Table 546. Axillary Hyperhidrosis Drug Tablets , by Region USD Million (2023-2028)
  • Table 547. Axillary Hyperhidrosis Drug Capsules , by Region USD Million (2023-2028)
  • Table 548. Axillary Hyperhidrosis Drug Liquid , by Region USD Million (2023-2028)
  • Table 549. Axillary Hyperhidrosis Drug: by Reasons(USD Million)
  • Table 550. Axillary Hyperhidrosis Drug Diabetes , by Region USD Million (2023-2028)
  • Table 551. Axillary Hyperhidrosis Drug Menopause hot flashes , by Region USD Million (2023-2028)
  • Table 552. Axillary Hyperhidrosis Drug Thyroid problems , by Region USD Million (2023-2028)
  • Table 553. Axillary Hyperhidrosis Drug Low blood sugar , by Region USD Million (2023-2028)
  • Table 554. Axillary Hyperhidrosis Drug Some types of cancer , by Region USD Million (2023-2028)
  • Table 555. Axillary Hyperhidrosis Drug Heart attack , by Region USD Million (2023-2028)
  • Table 556. Axillary Hyperhidrosis Drug Nervous system disorders , by Region USD Million (2023-2028)
  • Table 557. Axillary Hyperhidrosis Drug Infections , by Region USD Million (2023-2028)
  • Table 558. Axillary Hyperhidrosis Drug: by Diagnosis(USD Million)
  • Table 559. Axillary Hyperhidrosis Drug Blood , by Region USD Million (2023-2028)
  • Table 560. Axillary Hyperhidrosis Drug Urine , by Region USD Million (2023-2028)
  • Table 561. Axillary Hyperhidrosis Drug Other , by Region USD Million (2023-2028)
  • Table 562. South America Axillary Hyperhidrosis Drug, by Country USD Million (2023-2028)
  • Table 563. South America Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 564. South America Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 565. South America Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 566. South America Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 567. South America Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 568. South America Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 569. South America Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 570. South America Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 571. Brazil Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 572. Brazil Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 573. Brazil Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 574. Brazil Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 575. Brazil Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 576. Brazil Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 577. Brazil Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 578. Brazil Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 579. Argentina Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 580. Argentina Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 581. Argentina Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 582. Argentina Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 583. Argentina Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 584. Argentina Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 585. Argentina Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 586. Argentina Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 587. Rest of South America Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 588. Rest of South America Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 589. Rest of South America Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 590. Rest of South America Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 591. Rest of South America Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 592. Rest of South America Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 593. Rest of South America Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 594. Rest of South America Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 595. Asia Pacific Axillary Hyperhidrosis Drug, by Country USD Million (2023-2028)
  • Table 596. Asia Pacific Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 597. Asia Pacific Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 598. Asia Pacific Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 599. Asia Pacific Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 600. Asia Pacific Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 601. Asia Pacific Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 602. Asia Pacific Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 603. Asia Pacific Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 604. China Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 605. China Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 606. China Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 607. China Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 608. China Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 609. China Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 610. China Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 611. China Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 612. Japan Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 613. Japan Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 614. Japan Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 615. Japan Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 616. Japan Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 617. Japan Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 618. Japan Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 619. Japan Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 620. India Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 621. India Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 622. India Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 623. India Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 624. India Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 625. India Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 626. India Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 627. India Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 628. South Korea Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 629. South Korea Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 630. South Korea Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 631. South Korea Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 632. South Korea Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 633. South Korea Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 634. South Korea Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 635. South Korea Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 636. Taiwan Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 637. Taiwan Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 638. Taiwan Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 639. Taiwan Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 640. Taiwan Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 641. Taiwan Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 642. Taiwan Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 643. Taiwan Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 644. Australia Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 645. Australia Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 646. Australia Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 647. Australia Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 648. Australia Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 649. Australia Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 650. Australia Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 651. Australia Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 652. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 653. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 654. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 655. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 656. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 657. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 658. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 659. Rest of Asia-Pacific Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 660. Europe Axillary Hyperhidrosis Drug, by Country USD Million (2023-2028)
  • Table 661. Europe Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 662. Europe Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 663. Europe Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 664. Europe Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 665. Europe Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 666. Europe Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 667. Europe Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 668. Europe Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 669. Germany Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 670. Germany Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 671. Germany Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 672. Germany Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 673. Germany Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 674. Germany Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 675. Germany Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
  • Table 676. Germany Axillary Hyperhidrosis Drug, by Diagnosis USD Million (2023-2028)
  • Table 677. France Axillary Hyperhidrosis Drug, by Type USD Million (2023-2028)
  • Table 678. France Axillary Hyperhidrosis Drug, by Application USD Million (2023-2028)
  • Table 679. France Axillary Hyperhidrosis Drug, by Drug Type USD Million (2023-2028)
  • Table 680. France Axillary Hyperhidrosis Drug, by Hyperhidrosis Types USD Million (2023-2028)
  • Table 681. France Axillary Hyperhidrosis Drug, by Distribution Channel USD Million (2023-2028)
  • Table 682. France Axillary Hyperhidrosis Drug, by Form USD Million (2023-2028)
  • Table 683. France Axillary Hyperhidrosis Drug, by Reasons USD Million (2023-2028)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Axillary Hyperhidrosis Drug: by Type USD Million (2017-2022)
  • Figure 5. Global Axillary Hyperhidrosis Drug: by Application USD Million (2017-2022)
  • Figure 6. Global Axillary Hyperhidrosis Drug: by Drug Type USD Million (2017-2022)
  • Figure 7. Global Axillary Hyperhidrosis Drug: by Hyperhidrosis Types USD Million (2017-2022)
  • Figure 8. Global Axillary Hyperhidrosis Drug: by Distribution Channel USD Million (2017-2022)
  • Figure 9. Global Axillary Hyperhidrosis Drug: by Form USD Million (2017-2022)
  • Figure 10. Global Axillary Hyperhidrosis Drug: by Reasons USD Million (2017-2022)
  • Figure 11. Global Axillary Hyperhidrosis Drug: by Diagnosis USD Million (2017-2022)
  • Figure 12. South America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 13. Asia Pacific Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 14. Europe Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 15. MEA Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 16. North America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 17. Global Axillary Hyperhidrosis Drug: by Type K Tons (2017-2022)
  • Figure 18. Global Axillary Hyperhidrosis Drug: by Application K Tons (2017-2022)
  • Figure 19. Global Axillary Hyperhidrosis Drug: by Drug Type K Tons (2017-2022)
  • Figure 20. Global Axillary Hyperhidrosis Drug: by Hyperhidrosis Types K Tons (2017-2022)
  • Figure 21. Global Axillary Hyperhidrosis Drug: by Distribution Channel K Tons (2017-2022)
  • Figure 22. Global Axillary Hyperhidrosis Drug: by Form K Tons (2017-2022)
  • Figure 23. Global Axillary Hyperhidrosis Drug: by Reasons K Tons (2017-2022)
  • Figure 24. Global Axillary Hyperhidrosis Drug: by Diagnosis K Tons (2017-2022)
  • Figure 25. South America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 26. Asia Pacific Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 27. Europe Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 28. MEA Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 29. North America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 30. Global Axillary Hyperhidrosis Drug: by Type USD/Units (2017-2022)
  • Figure 31. Global Axillary Hyperhidrosis Drug share by Players 2022 (%)
  • Figure 32. Global Axillary Hyperhidrosis Drug share by Players (Top 3) 2022(%)
  • Figure 33. Global Axillary Hyperhidrosis Drug share by Players (Top 5) 2022(%)
  • Figure 34. BCG Matrix for key Companies
  • Figure 35. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 36. Allergan Plc (Ireland) Revenue: by Geography 2022
  • Figure 37. Brickell Biotech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Brickell Biotech Inc. (United States) Revenue: by Geography 2022
  • Figure 39. Dermira Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Dermira Inc. (United States) Revenue: by Geography 2022
  • Figure 41. Dr. August Wolff GmbH & Co KG Arzneimittel (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Dr. August Wolff GmbH & Co KG Arzneimittel (Germany) Revenue: by Geography 2022
  • Figure 43. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 45. TheraVida Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. TheraVida Inc. (United States) Revenue: by Geography 2022
  • Figure 47. Revance Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 48. Revance Therapeutics, Inc. (United States) Revenue: by Geography 2022
  • Figure 49. Ulthera, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 50. Ulthera, Inc. (United States) Revenue: by Geography 2022
  • Figure 51. Global Axillary Hyperhidrosis Drug: by Type USD Million (2023-2028)
  • Figure 52. Global Axillary Hyperhidrosis Drug: by Application USD Million (2023-2028)
  • Figure 53. Global Axillary Hyperhidrosis Drug: by Drug Type USD Million (2023-2028)
  • Figure 54. Global Axillary Hyperhidrosis Drug: by Hyperhidrosis Types USD Million (2023-2028)
  • Figure 55. Global Axillary Hyperhidrosis Drug: by Distribution Channel USD Million (2023-2028)
  • Figure 56. Global Axillary Hyperhidrosis Drug: by Form USD Million (2023-2028)
  • Figure 57. Global Axillary Hyperhidrosis Drug: by Reasons USD Million (2023-2028)
  • Figure 58. Global Axillary Hyperhidrosis Drug: by Diagnosis USD Million (2023-2028)
  • Figure 59. South America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 60. Asia Pacific Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 61. Europe Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 62. MEA Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 63. North America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 64. Global Axillary Hyperhidrosis Drug: by Type K Tons (2023-2028)
  • Figure 65. Global Axillary Hyperhidrosis Drug: by Application K Tons (2023-2028)
  • Figure 66. Global Axillary Hyperhidrosis Drug: by Drug Type K Tons (2023-2028)
  • Figure 67. Global Axillary Hyperhidrosis Drug: by Hyperhidrosis Types K Tons (2023-2028)
  • Figure 68. Global Axillary Hyperhidrosis Drug: by Distribution Channel K Tons (2023-2028)
  • Figure 69. Global Axillary Hyperhidrosis Drug: by Form K Tons (2023-2028)
  • Figure 70. Global Axillary Hyperhidrosis Drug: by Reasons K Tons (2023-2028)
  • Figure 71. Global Axillary Hyperhidrosis Drug: by Diagnosis K Tons (2023-2028)
  • Figure 72. South America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 73. Asia Pacific Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 74. Europe Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 75. MEA Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 76. North America Axillary Hyperhidrosis Drug Share (%), by Country
  • Figure 77. Global Axillary Hyperhidrosis Drug: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Allergan Plc (Ireland)
  • Brickell Biotech Inc. (United States)
  • Dermira Inc. (United States)
  • Dr. August Wolff GmbH & Co KG Arzneimittel (Germany)
  • GlaxoSmithKline Plc (United Kingdom)
  • TheraVida Inc. (United States)
  • Revance Therapeutics, Inc. (United States)
  • Ulthera, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 203 Pages 69 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Axillary Hyperhidrosis Drug Market Quantitative research analysis
Global Axillary Hyperhidrosis Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Axillary Hyperhidrosis Drug market are Allergan Plc (Ireland), Brickell Biotech Inc. (United States), Dermira Inc. (United States), Dr. August Wolff GmbH & Co KG Arzneimittel (Germany), GlaxoSmithKline Plc (United Kingdom), TheraVida Inc. (United States), Revance Therapeutics, Inc. (United States) and Ulthera, Inc. (United States).
In this highly competitive & fast evolving Axillary Hyperhidrosis Drug industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Clinic, Hospital, Home Care and Others are the potential customers of Axillary Hyperhidrosis Drug industry.

Know More About Global Axillary Hyperhidrosis Drug Market Report?

Have a Query? Click Here

Other Related Reports

Heparin Calcium Comprehensive Study by Type (Unfractionated Heparin, Low molecular Heparin API), Application (Heart Attacks and Bypass Surgeries, Kidney Dialysis Processes, Extracorporeal Life Suppo...
$ 3650
Nanostructured Drug Comprehensive Study by Type (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion and Nanoemulsion, Nanosuspension), Application (Cardiovascular/Chronic, Immuno...
$ 3650
Vegetable Capsules Comprehensive Study by Type (HPMC with Gelling Agent, HPMC without Gelling Agent, Plant Polysaccarides, Starch, Pullulan), Application (Supplements, Medicine, Cosmetics), End Use...
$ 3450
Angioedema Treatment Comprehensive Study by Type (Antihistamines, Corticosteroids, Others), Application (Hospitals, Clinics, Research Organizations ), Drugs (C1 Esterase Inhibitor, Selective Bradykin...
$ 3450
Sodium Chloride Injection Comprehensive Study by Application (Hospitals, Clinics, Other Medical Institutions), Container (Flexible Bag, Plastic Bottles, Glass Bottles), Distribution Channel (Online, ...
$ 3500
Lactulose Concentrate Comprehensive Study by Type (Chemical Synthesis, Enzymatic Method), Application (Pharmaceuticals, Food Industry, Other) Players and Region - Global Market Outlook to 2026
$ 3500